Central Valley Advisors LLC Buys 488 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Central Valley Advisors LLC raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 9.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 5,612 shares of the medical research company’s stock after acquiring an additional 488 shares during the period. Central Valley Advisors LLC’s holdings in IQVIA were worth $1,419,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Kestra Advisory Services LLC boosted its stake in IQVIA by 39.1% in the 3rd quarter. Kestra Advisory Services LLC now owns 5,344 shares of the medical research company’s stock worth $1,051,000 after purchasing an additional 1,502 shares during the period. V Square Quantitative Management LLC bought a new stake in shares of IQVIA in the 3rd quarter valued at about $181,000. Mariner LLC raised its holdings in IQVIA by 9.0% in the 3rd quarter. Mariner LLC now owns 14,566 shares of the medical research company’s stock valued at $2,866,000 after acquiring an additional 1,197 shares during the period. Northern Trust Corp raised its holdings in IQVIA by 1.8% in the 3rd quarter. Northern Trust Corp now owns 1,737,315 shares of the medical research company’s stock valued at $341,817,000 after acquiring an additional 31,413 shares during the period. Finally, Cary Street Partners Investment Advisory LLC increased its holdings in shares of IQVIA by 10.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,071 shares of the medical research company’s stock worth $211,000 after purchasing an additional 97 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent research reports. Truist Financial lowered their target price on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Friday. The Goldman Sachs Group assumed coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Robert W. Baird reduced their price target on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research report on Friday, May 3rd. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $258.40.

Check Out Our Latest Analysis on IQV

IQVIA Trading Down 1.2 %

Shares of IQV stock traded down $2.65 during trading hours on Tuesday, hitting $211.44. 224,794 shares of the company’s stock traded hands, compared to its average volume of 1,012,141. The stock’s 50 day simple moving average is $225.23 and its 200 day simple moving average is $230.38. The stock has a market cap of $38.52 billion, a PE ratio of 29.24, a price-to-earnings-growth ratio of 1.97 and a beta of 1.54. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQVGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.11. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.